Home Featured Page 21

Featured

Latest

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Ketamine-Assisted Therapy at Work? The Future of Employee Benefits

Psychedelics on the Ballot 2024

Psychedelics Advocates Urge Yes on Question 4 Amid Last-Minute Debates

Bipartisan Momentum or Radical Reform? Insiders Weigh In on the Future...

Psychedelics Lately – Massachusetts’ Question 4 and Updates in Psychedelics and...

Pα+ Psychedelic Bulletin #179: VA Funds MDMA for PTSD and AUD...

OP-Ed: From a Massachusetts Psychiatrist: Why Doctors Support Yes on Question...

Is Cannabis Psychedelic? Examining the Scientific Evidence

Backed by $15m in NIDA Funding, NYU and B.More Team Up...

Compass Pathways Pushes Back Phase 3 Readouts, Lays Off 30% of...

1...202122...295 Page 21 of 295

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Ketamine-Assisted Therapy at Work? The Future of Employee Benefits

Psychedelics on the Ballot 2024

Psychedelics Advocates Urge Yes on Question 4 Amid Last-Minute Debates

Bipartisan Momentum or Radical Reform? Insiders Weigh In on the Future...

Psychedelics Lately – Massachusetts’ Question 4 and Updates in Psychedelics and...

Pα+ Psychedelic Bulletin #179: VA Funds MDMA for PTSD and AUD...

OP-Ed: From a Massachusetts Psychiatrist: Why Doctors Support Yes on Question...

Is Cannabis Psychedelic? Examining the Scientific Evidence

Backed by $15m in NIDA Funding, NYU and B.More Team Up...

Compass Pathways Pushes Back Phase 3 Readouts, Lays Off 30% of...

EDITOR PICKS

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY